Document is current

Article History

Received: 24 May 2022

Accepted: 30 August 2022

First Online: 27 September 2022

Declarations

:

: D. Isla has received consulting fees from AbbVie, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, F. Hoffmann-La Roche, Lilly, Merck, MSD, Pfizer, Sanofi, and Takeda, has received speaker Honoraria from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, F. Hoffmann-La Roche, MSD, Pfizer, and Takeda, has participated in Clinical Trials sponsored AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, F. Hoffmann-La Roche, Janssen, Lilly, Merck, Mirati, MSD, Novartis, Pfizer, and Sanofi, and has received research grant from BMS, F. Hoffmann-La Roche, GSK, Lilly, Merck, and MSD. A. Insa has served in the advisory board role for Bristol, MSD, Pfizer, Roche, and Amgen, has received expert testimony from Bristol, Pfizer, Roche, and AstraZeneca, has received travel expenses from Bristol, MSD, and Roche. E. Felip has received honoraria for advisory board and speaker´s bureau from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffman-La Roche, GlaxoSmithKline, Janssen, Medical Trends, Medscape, Merck KGaA, Merck Sharp and Dohme, Novartis, Peptomyc, PeerVoice, Pfizer, Regeneron, Sanofi Genzyme, Seattle Genetics and Takeda, she is an independent board member in Grifols, and she has received research funding from Fundación Merck Salud, and grant for oncology Innovation, Merck and Healthcare KGaA. P. Garrido has served on an advisory role for Abbvie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol (BMS), GlaxoSmithKline (GSK), Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Takeda, Sanofi, she has received speaker honoraria from AstraZeneca, Boehringer Ingelheim, Bristol (BMS), Janssen, MSD, Medscape, Novartis, Pfizer, Roche, Takeda, and TouchTime. J. Remon has served on an advisory board for MSD, Boehringer Ingelheim, BMS, Astrazeneca, Roche; Bayer, Takeda and Janssen, has received speaker honoraria from Pfizer, and MSD, has received travel reimbursement from Ose immunotherapeutics, BMS, Astrazeneca, and Roche, and he is a co-editor in CTO. J.M. Trigo has served on an advisory board for MSD, Boehringer Ingelheim, BMS, Takeda, Janssen, Bayer, and EISAI, has received speaker honoraria from Pfizer, MSD, AstraZeneca, EISAI, and Bayer, and has received travel reimbursement from BMS, AstraZeneca, Roche, and MSD. J. De Castro has received honoraria for consultancy/advisory board from AstraZeneca, Boehringer Ingelheim, Clovis, Pfizer, and Roche.

: This study does not involve patient data collection, and therefore, the approval of an ethics committee(s) was not required.

: Data gathered for this Delphi study are entirely based on the feedback provided by the panel of experts on the questionnaire statements. This study does not involve participation of patients, and therefore, informed consent is not required.